Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis
|
By LabMedica International staff writers Posted on 04 Mar 2021 |
|
Illustration
Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell analysis and further explore AI technology in vitro diagnostics.
Through this cooperation, the two parties will further develop blood cell morphology testing equipment and system applications with world-class imaging quality and cell recognition capabilities. Large-scale production in the future is expected to relieve the work pressure faced by primary endoscopy physicians, and improve the diagnosis and diagnosis of blood diseases.
Tencent AI Lab will use machine learning, computer vision and other cutting-edge algorithms and the experience of its research scientists, Tencent Cloud’s comprehensive solutions, combined with Mindray Medical’s expertise in slide processing, imaging systems, integrated design, and clinical experts, massive data and other aspects, to jointly develop an automated blood cell analyzer in order to further improve accuracy in results. The automated blood cell analyzer will detect cell quality changes and have high levels of cell identification capability. At the same time, it will provide a cost advantage as compared to rival products with higher prices.
In addition to morphological testing, Tencent AI Lab will also work with Mindray Medical to explore the integration and application of AI technology in other areas of in vitro diagnostics, such as urine analysis, smart laboratory, and in vitro diagnostic big data, in order to provide better quality medical equipment and services.
“AI+Medical/Pharmaceutical" is one of Tencent's AI Lab's long-term core research directions. We are very happy to cooperate with industry top partners like Mindray to enable technology to help medical care, assist doctors, and serve patients,” said Yang Wei, General Manager of Tencent AI Lab.
“With Mindray’s deep understanding of clinical needs and accumulation of detection technology over the years, and Tencent’s leading exploration in artificial intelligence technology, The results of the cooperation between the two parties will greatly improve the ability of clinical intelligent detection,” said Yan Huawen, General Manager of Mindray’s IVD Division.
Related Links:
Mindray
Tencent AI Lab
Through this cooperation, the two parties will further develop blood cell morphology testing equipment and system applications with world-class imaging quality and cell recognition capabilities. Large-scale production in the future is expected to relieve the work pressure faced by primary endoscopy physicians, and improve the diagnosis and diagnosis of blood diseases.
Tencent AI Lab will use machine learning, computer vision and other cutting-edge algorithms and the experience of its research scientists, Tencent Cloud’s comprehensive solutions, combined with Mindray Medical’s expertise in slide processing, imaging systems, integrated design, and clinical experts, massive data and other aspects, to jointly develop an automated blood cell analyzer in order to further improve accuracy in results. The automated blood cell analyzer will detect cell quality changes and have high levels of cell identification capability. At the same time, it will provide a cost advantage as compared to rival products with higher prices.
In addition to morphological testing, Tencent AI Lab will also work with Mindray Medical to explore the integration and application of AI technology in other areas of in vitro diagnostics, such as urine analysis, smart laboratory, and in vitro diagnostic big data, in order to provide better quality medical equipment and services.
“AI+Medical/Pharmaceutical" is one of Tencent's AI Lab's long-term core research directions. We are very happy to cooperate with industry top partners like Mindray to enable technology to help medical care, assist doctors, and serve patients,” said Yang Wei, General Manager of Tencent AI Lab.
“With Mindray’s deep understanding of clinical needs and accumulation of detection technology over the years, and Tencent’s leading exploration in artificial intelligence technology, The results of the cooperation between the two parties will greatly improve the ability of clinical intelligent detection,” said Yan Huawen, General Manager of Mindray’s IVD Division.
Related Links:
Mindray
Tencent AI Lab
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Rapid Molecular Testing Device
FlashDetect Flash10
Latest Industry News
- Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
- QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
- WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
Channels
Clinical Chemistry
view channel
New Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read more
Molecular Diagnostics
view channel
Ultra-Sensitive DNA Test Identifies Relapse Risk in Aggressive Leukemia
Acute myeloid leukemia (AML) is a rare but aggressive blood cancer in which relapse after allogeneic stem cell transplant remains a major clinical challenge, particularly for patients with NPM1-mutated disease.... Read more
Blood Test Could Help Detect Gallbladder Cancer Earlier
Gallbladder cancer is one of the deadliest gastrointestinal cancers because it is often diagnosed at an advanced stage when treatment options are limited. Early symptoms are minimal, and current screening... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Hidden Gut Viruses Linked to Colorectal Cancer Risk
Colorectal cancer (CRC) remains a leading cause of cancer mortality in many Western countries, and existing risk-stratification approaches leave substantial room for improvement. Although age, diet, and... Read more
Three-Test Panel Launched for Detection of Liver Fluke Infections
Parasitic liver fluke infections remain endemic in parts of Asia, where transmission commonly occurs through consumption of raw freshwater fish or aquatic plants. Chronic infection is a well-established... Read more
Pathology
view channel
Molecular Imaging to Reduce Need for Melanoma Biopsies
Melanoma is the deadliest form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Because early melanomas can closely resemble benign moles, clinicians often rely on visual... Read more
Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
Urine testing is a critical, non-invasive diagnostic tool used to detect conditions such as pregnancy, urinary tract infections, metabolic disorders, cancer, and kidney disease. However, contaminated or... Read more
Technology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more